Scarica l'app Stockscreener
8.71
0.17%
-0.03
Precedente Chiudi:
$8.74
Aprire:
$8.94
Volume 24 ore:
17,491
Relative Volume:
0.04
Capitalizzazione di mercato:
$617.46M
Reddito:
-
Utile/perdita netta:
$-100.70M
Rapporto P/E:
-3.9954
EPS:
-2.18
Flusso di cassa netto:
$-86.54M
1 W Prestazione:
-1.19%
1M Prestazione:
-4.33%
6M Prestazione:
-1.86%
1 anno Prestazione:
+22.71%
Intervallo 1D:
$8.68
$9.00
Intervallo di 1 settimana:
$8.105
$9.11
Portata 52W:
$6.33
$16.65
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Confronta ORIC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ORIC | 8.76 | 617.46M | 0 | -100.70M | -86.54M | -2.18 |
| VRTX | 447.65 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.27 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.49 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside - MSN
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Research Analysts Issue Forecasts for ORIC FY2024 Earnings - Defense World
Oric Pharmaceuticals Inc (ORIC-Q) QuotePress Release - The Globe and Mail
Wedbush Lowers Earnings Estimates for ORIC Pharmaceuticals - Defense World
(ORIC) Trading Advice - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World
Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks
Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com
Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com
ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World
ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Long Term Trading Analysis for (ORIC) - Stock Traders Daily
Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World
Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology
ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia
ORIC-114 shows promise in preclinical cancer study - Investing.com
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire
Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex
ORIC Pharmaceuticals Inc (ORIC) shows promising results - US Post News
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors - StockTitan
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
SG Americas Securities LLC Takes $714,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
The Manufacturers Life Insurance Company Buys 9,424 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Squarepoint Ops LLC Buys 16,613 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Proactive Strategies - Stock Traders Daily
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
ORIC® Pharmaceuticals Announces Presentation at the - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
XTX Topco Ltd Invests $153,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Profund Advisors LLC Increases Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals Inc Inc. (ORIC) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Trading Day Review: ORIC Pharmaceuticals Inc (ORIC) Loses Momentum, Closing at 10.00 - The Dwinnex
Cantor Fitzgerald Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Defense World
ORIC’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Brokers Set Expectations for ORIC Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:ORIC) - Defense World
Rhumbline Advisers Has $655,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals’ (ORIC) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Stocks of ORIC Pharmaceuticals Inc (ORIC) are poised to climb above their peers - SETE News
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Victory Capital Management Inc. - Defense World
(ORIC) On The My Stocks Page - Stock Traders Daily
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oric Pharmaceuticals Inc Azioni (ORIC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chacko Jacob | PRESIDENT AND CEO |
Mar 06 '24 |
Sale |
16.21 |
40,000 |
648,380 |
728,544 |
| Chacko Jacob | PRESIDENT AND CEO |
Feb 07 '24 |
Sale |
12.29 |
26,042 |
320,186 |
768,544 |
| Chacko Jacob | PRESIDENT AND CEO |
Feb 06 '24 |
Sale |
12.12 |
13,958 |
169,160 |
794,586 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
14,042 |
0 |
29,091 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '23 |
Sale |
8.59 |
5,282 |
45,351 |
23,809 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '23 |
Sale |
8.58 |
5,282 |
45,338 |
83,809 |
| Chacko Jacob | President and CEO |
Dec 15 '23 |
Option Exercise |
0.00 |
38,667 |
0 |
823,083 |
| Chacko Jacob | President and CEO |
Dec 15 '23 |
Sale |
8.58 |
14,539 |
124,813 |
808,544 |
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):